(Q44526398)

English

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

scientific article published on 3 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

Maria Di Bartolomeo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Filippo Pietrantonio

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Federica Perrone

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Lorenza Rimassa

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

C Bertan

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

E Beretta

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

C Carbone

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

P Biondani

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

R Passalacqua

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

S Pilotti

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

E Bajetta

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Italian Trials in Medical Oncology Group

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

3 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

Targeted oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

155-162

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821376%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

New options and old dilemmas in the treatment of patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0283-8

21 January 2018

p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821376

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821376

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821376

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821376

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P53 abnormalities and outcomes in colorectal cancer: a systematic review.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821376

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44526398&oldid=2206711593"